Part 3/10:
Prior negotiations had yielded a more comprehensive deal that contained reforms aimed at curtailing the power of Pharmacy Benefit Managers (PBMs) and increasing funding for pediatric cancer research. However, after significant pushback from Musk and other influential Republicans, these negotiations dissolved, leading to chaos in the ongoing funding discussions.